DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
L Carrassa, G Damia - Cancer treatment reviews, 2017 - Elsevier
Over the last decade the unravelling of the molecular mechanisms of the DNA damage
response pathways and of the genomic landscape of human tumors have paved the road to …
response pathways and of the genomic landscape of human tumors have paved the road to …
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian …
Purpose: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes
TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy …
TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy …
A phase ib study Assessing the safety, tolerability, and efficacy of the first-in-class WEE1 inhibitor adavosertib (AZD1775) as monotherapy in patients with advanced …
TM Bauer, KN Moore, JS Rader, F Simpkins, AC Mita… - Targeted …, 2023 - Springer
Background Adavosertib (AZD1775) is a first-in-class, selective, small-molecule inhibitor of
Wee1. Objective The safety, tolerability, pharmacokinetics, and efficacy of adavosertib …
Wee1. Objective The safety, tolerability, pharmacokinetics, and efficacy of adavosertib …
[PDF][PDF] Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: dose escalation
E Hamilton, GS Falchook, JS Wang, S Fu, A Oza… - Cancer …, 2019 - clearityfoundation.org
• Adavosertib (AZD1775) is a highly selective small-molecule WEE1 inhibitor being
developed as a treatment for advanced solid tumors and has shown single-agent activity in …
developed as a treatment for advanced solid tumors and has shown single-agent activity in …